Filing Details

Accession Number:
0001209191-21-013353
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-23 18:04:59
Reporting Period:
2021-02-22
Accepted Time:
2021-02-23 18:04:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1549595 Nurix Therapeutics Inc. NRIX Pharmaceutical Preparations (2834) 270838048
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1817217 Hans Houte Van C/O Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco CA 94158
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-22 1,417 $0.84 1,417 No 4 M Direct
Common Stock Acquisiton 2021-02-22 3,913 $1.20 5,330 No 4 M Direct
Common Stock Disposition 2021-02-22 5,330 $39.93 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-02-22 1,417 $0.00 1,417 $0.84
Common Stock Employee Stock Option (right to buy) Disposition 2021-02-22 3,913 $0.00 3,913 $1.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
68,333 2026-04-26 No 4 M Direct
29,420 2028-03-01 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. Represents the weighted average sale price. The lowest price at which shares were sold was $39.90 and the highest price at which shares were sold was $40.03. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
  3. The option is fully vested.
  4. The stock option vests as to 1/48 of the total shares monthly beginning February 2, 2018 until the option is fully vested on January 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.